Clinical Trials

Doctor%2Band%2Bpatient%2B-adobe.jpg

Study: VT-101 and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

  • Indications: Anatomic Stage IV Breast Cancer AJCC v8; ERBB2 Overexpression; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Refractory Breast Carcinoma

  • Phase: Phase I